The clinical-stage pharmaceutical company Iterum Therapeutics plc (NASDAQ: ITRM) recently reported its Q1-2021 financial results. The shares of ITRM were up 17.89% on Monday, anticipating its new drug application with the FDA for a potential treatment for UTI. Pitching oral sulopenem for UTI treatment Sulopenem etzadroxil/probenecid is pitched for uncomplicated […]